FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 145 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... January 30, 2024 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. January 9, 2020 Load more HOT NEWS Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... For Some Women with Breast Cancer, Cost Influences Decisions about Surgery Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer
